November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter [Seeking Alpha]
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS [Yahoo! Finance]
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
Grail: Downgraded From Speculative Buy To Hold As The Stock Price Appreciated Faster Than Expected [Seeking Alpha]
Exact Sciences (NASDAQ:EXAS) was given a new $105.00 price target on by analysts at Stifel Nicolaus.